The role of PSA-based screening for prostate cancer is still under debate. But many men are advised by their general practitioner to have their PSA levels checked regularly. This is the easiest way to identify those men that have an increased risk of having prostate cancer. It also may help to detect prostate cancer at an early and curable stage. But when your doctor then tells you that you have an elevated PSA, a lot of questions come to mind: Do I really have prostate cancer? What to do next? Do I really need a prostate biopsy to know if I have prostate cancer? Are there other ways to rule out the presence of prostate cancer that are quick, reliable, and avoid the side effects of an invasive biopsy?

Your options in short


prostate cancer diagnosis overview alternatives prostate biopsy


Do you want your doctor to consider or perform a SelectMDx test, download the brochure and take it with you to your doctor.


If you have a question that is not discussed here, you can always check the FAQs or ask your question to the editorial board.


1. Shariat SF and Roehrborn CG. Using biopsy to detect prostate cancer. Rev Urol. 2008;10:262-80

2. Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 2016;70:740-8

3. Haese A, Troostens G, Steyaert S, et al. Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer before initial prostate biopsy. J Urol 2019;202:256-63

4. Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Onco 2016;39:97-106

5. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389:815-22

6. Guneyli S, Erdem CZ, Erdem LO. Magnetic resonance imaging of prostate cancer. Clinical Imaging 2016;40:601-9

7. Poyet C, Nieboer D, Bhindi B, et al. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. BJU Int 2016;117:401-8

8. McGrath S, Christidis D, Perera M, et al. Prostate cancer biomarkers: Are we hitting the mark? Prostate Int 2016;4:130-5

9. Hendriks RJ, van Oort IM, Schalken JA. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis 2017;20:12-9